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Among patients undergoing pacemaker or implantable cardioverter-defibrillator 
(ICD) implantation, approximately 14-45% are on anticoagulation therapy.1 Recently 
updated guidelines from the American College of Chest Physicians have recommended 
use of bridging anticoagulation with therapeutic dose of subcutaneous low-molecular-
weight heparin or intravenous heparin in patients with mechanical heart valves, 
atrial fibrillation, or venous thromboembolism who are at moderate or high risk for 
thromboembolic events (estimated annual stroke risk >5%). While this strategy may 
be appropriate in cases involving major surgery, this may not be applicable to device-
based procedures where implantations typically occur above the pectoral fascia. In fact, 
significant hematomas have been shown to occur in approximately 30% of patients 
managed with heparin bridging in this setting.2
It has recently been suggested that device implantation without discontinua-
tion of oral anticoagulation (OAC) is a safe and efficient approach, with reduced 
thromboembolic risk, bleeding risks, and reduced hospital inpatient stay. In a 2012 
meta-analysis that included 5978 patients from 13 studies (which included only one 
prospective randomized trial of 101 patients), the overall rate of bleeding complica-
tions (hematoma at device pocket, transfusion, or prolonged hospital stay) was 3.7%, 
ranging from 2.2% in those receiving no anticoagulation to 14.6% in persons whose 
chronic OAC was stopped and bridging therapy with heparin administered. While 
the odds of bleeding were significantly higher in those patients with heparin bridging 
strategy (adjusted odds ratio-OR 8.3; 95% confidence intervals-CI 5.5-12.9) or dual 
antiplatelet therapy (adjusted OR 5.0; 95% CI 3.0-8.3) compared with those receiving 
no anticoagulation, those patients who continued oral anticoagulation (adjusted OR 
1.6; 95% CI 0.9-2.6) or were taking aspirin alone (adjusted OR 1.5; 95% CI 0.9-2.3) 
showed only a non-significant trend toward higher bleeding.3
Subsequent to the 2012 meta-analysis, the BRUISE CONTROL investigators per-
formed the largest randomized trial of antithrombotic treatment strategies in patients 
undergoing cardiac devices implantation. Among 681 patients with an annualized 
risk of thromboembolic events of 5% or greater and taking long-term warfarin, those 
randomized to device insertion while on continued warfarin therapy had a significantly 
lower incidence of the primary outcome (clinically significant pocket hematoma re-
quiring prolonged hospital stay, interruption of anticoagulation therapy, or surgery for 
evacuation) compared with those whose warfarin was stopped and heparin-bridging 
therapy was used (3.5% versus 16%; relative risk 0.19; 95% CI 0.10-0.36).4
There are several explanations for why continuing warfarin may be safe. Most of 
these procedures involve implantation of the device above the pectoral fascia and 
thus avoid the more vascular areas of the chest. Second, electrocautery is often used 
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to improve hemostasis. Patients who are fully anticoagulated 
and develop oozing at the time of the procedure will likely have 
that cauterized before the incision is closed. Individuals who 
are not anicoagulated at the time of the procedure may have 
subclinical bleeding that is only later unmasked when antico-
agulation is reinitiated. Third, the amount of the time during 
which the patient is not anticoagulated is minimized and even 
eliminated. Fourth, and perhaps most important, continuing 
warfarin avoids the need for heparin and the increased risk 
of bleeding associated with post-procedural administration. 
This is particularly beneficial because heparin administration 
requires extended hospital stays, frequent monitoring and he-
matologic complications including periods of sub-therapeutic 
anticoagulation and heparin-induced thrombocytopenia.
Three new oral anticoagulant agents, dabigatran (a direct 
thrombin inhibitor), rivaroxaban and apixaban (Xa elective 
inhibitors), have been approved within the past few years for 
the prevention of stroke in patients with nonvalvular atrial 
fibrillation. These agents have short half-lives, with maximal 
anticoagulant effects observed soon after oral intake and 
reduction of the effects soon after cessation. A retrospective 
study published by Rowley et al in May 2013 compared unin-
terrupted dabigatran with uninterrupted warfarin in patients 
undergoing cardiac device implantation. The study concluded 
that there is a similar risk of bleeding complications in either 
group. However, it is important to note that the study was 
retrospective, comparing two separate cohorts.5
Based on available data, for patients requiring cardiac 
device implantation, who have the highest risk of thrombo-
embolic events (greater than 5% per year), in whom the risk 
of discontinuing antithrombotic therapy is thought to exceed 
the risks of post-procedural bleedings, continuation of chronic 
OAC therapy is recommended rather than a bridging strategy 
using heparin.
For patients with a lower risk of thromboembolic events 
(5% per year or less), there are no outcomes data to guide the 
decision to continue or temporarily suspend antithrombotic 
therapy at the time of the procedure. Based on individualized 
assessment of risks and benefits, field experts feel that it is rea-
sonable to discontinue antithrombotic therapy two days prior 
to the procedure and, in the absence of any post-procedure 
bleeding, to resume antithrombotic therapy on the day fol-
lowing the procedure. This approach should be taken without 
any bridging anticoagulation. However, it is also reasonable 
to continue antithrombotic therapy without interruption in 
selected patients.6
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